LXRX
Price
$1.25
Change
+$0.04 (+3.31%)
Updated
Sep 24, 12:10 PM (EDT)
Capitalization
439.71M
36 days until earnings call
TECH
Price
$51.32
Change
-$1.60 (-3.02%)
Updated
Sep 24, 12:31 PM (EDT)
Capitalization
8.24B
41 days until earnings call
Interact to see
Advertisement

LXRX vs TECH

Header iconLXRX vs TECH Comparison
Open Charts LXRX vs TECHBanner chart's image
Lexicon Pharmaceuticals
Price$1.25
Change+$0.04 (+3.31%)
Volume$4K
Capitalization439.71M
Bio-Techne
Price$51.32
Change-$1.60 (-3.02%)
Volume$1K
Capitalization8.24B
LXRX vs TECH Comparison Chart in %
Loading...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LXRX vs. TECH commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LXRX is a StrongBuy and TECH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (LXRX: $1.21 vs. TECH: $52.92)
Brand notoriety: LXRX and TECH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LXRX: 90% vs. TECH: 101%
Market capitalization -- LXRX: $439.71M vs. TECH: $8.24B
LXRX [@Biotechnology] is valued at $439.71M. TECH’s [@Biotechnology] market capitalization is $8.24B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LXRX’s FA Score shows that 1 FA rating(s) are green whileTECH’s FA Score has 2 green FA rating(s).

  • LXRX’s FA Score: 1 green, 4 red.
  • TECH’s FA Score: 2 green, 3 red.
According to our system of comparison, both LXRX and TECH are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LXRX’s TA Score shows that 6 TA indicator(s) are bullish while TECH’s TA Score has 3 bullish TA indicator(s).

  • LXRX’s TA Score: 6 bullish, 2 bearish.
  • TECH’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, LXRX is a better buy in the short-term than TECH.

Price Growth

LXRX (@Biotechnology) experienced а +10.00% price change this week, while TECH (@Biotechnology) price change was +2.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.31%. For the same industry, the average monthly price growth was +10.09%, and the average quarterly price growth was +53.86%.

Reported Earning Dates

LXRX is expected to report earnings on Oct 30, 2025.

TECH is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (+4.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TECH($8.24B) has a higher market cap than LXRX($440M). LXRX YTD gains are higher at: 63.846 vs. TECH (-26.212). TECH has higher annual earnings (EBITDA): 217M vs. LXRX (-107.44M). TECH has more cash in the bank: 162M vs. LXRX (139M). LXRX has less debt than TECH: LXRX (57M) vs TECH (444M). TECH has higher revenues than LXRX: TECH (1.22B) vs LXRX (58.4M).
LXRXTECHLXRX / TECH
Capitalization440M8.24B5%
EBITDA-107.44M217M-50%
Gain YTD63.846-26.212-244%
P/E RatioN/A115.04-
Revenue58.4M1.22B5%
Total Cash139M162M86%
Total Debt57M444M13%
FUNDAMENTALS RATINGS
LXRX vs TECH: Fundamental Ratings
LXRX
TECH
OUTLOOK RATING
1..100
786
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9887
PRICE GROWTH RATING
1..100
3763
P/E GROWTH RATING
1..100
1914
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECH's Valuation (4) in the Biotechnology industry is somewhat better than the same rating for LXRX (53). This means that TECH’s stock grew somewhat faster than LXRX’s over the last 12 months.

TECH's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as LXRX (100). This means that TECH’s stock grew similarly to LXRX’s over the last 12 months.

TECH's SMR Rating (87) in the Biotechnology industry is in the same range as LXRX (98). This means that TECH’s stock grew similarly to LXRX’s over the last 12 months.

LXRX's Price Growth Rating (37) in the Biotechnology industry is in the same range as TECH (63). This means that LXRX’s stock grew similarly to TECH’s over the last 12 months.

TECH's P/E Growth Rating (14) in the Biotechnology industry is in the same range as LXRX (19). This means that TECH’s stock grew similarly to LXRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LXRXTECH
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
56%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
70%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 13 days ago
85%
Bullish Trend 6 days ago
73%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 2 days ago
72%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FRIQX12.28N/A
N/A
Fidelity Advisor Real Estate Income M
AFCMX19.24-0.05
-0.26%
American Century Focused Intl Gr R6
MSOIX39.07-0.10
-0.26%
NYLI WMC Enduring Capital Class I
GQSCX14.99-0.06
-0.40%
Glenmede Disciplined US Small Cap Eq Ptf
GSMYX24.67-0.17
-0.68%
Goldman Sachs Small/Mid Cap Growth Instl

LXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with PLRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
+4.31%
PLRX - LXRX
39%
Loosely correlated
-2.67%
OCUL - LXRX
37%
Loosely correlated
+0.41%
TECH - LXRX
34%
Loosely correlated
-0.23%
EPIX - LXRX
34%
Loosely correlated
-4.93%
NMRA - LXRX
32%
Poorly correlated
+10.40%
More

TECH and

Correlation & Price change

A.I.dvisor indicates that over the last year, TECH has been loosely correlated with SYRE. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if TECH jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TECH
1D Price
Change %
TECH100%
-0.23%
SYRE - TECH
48%
Loosely correlated
+4.77%
MRVI - TECH
47%
Loosely correlated
-0.36%
MRNA - TECH
46%
Loosely correlated
-2.90%
XNCR - TECH
44%
Loosely correlated
-0.67%
FTRE - TECH
44%
Loosely correlated
-2.80%
More